Cannabis sativa L. extract (THC< 0.1%)
Linnea extracts and manufactures Cannabis as a botanical ingredient for pharmaceutical purposes.
A growing number of clinical studies indicates that Cannabis and its phytocannabinoids may have a relevant medicinal value for certain diseases. The mechanisms of action of the single cannabinoids and their interaction in biological human system are also becoming increasingly clear.
The discovery of the endocannabinoid system and its physiological functions contribute to understanding a significant potential role of Cannabis in medicine.
CBD or cannabidiol, is one of the major non-psychotropic cannabinoid found in Cannabis. It has shown antiepileptic, anti-inflammatory, anti-emetic, muscle relaxing, anxiolytic, neuroprotective and anti-psychotic-like activity and reduces the psychoactive effects of THC (tetrahydrocannabinol).
SWISS GMP MANUFUCATURING
Linnea Cannabis Extract is obtained exclusively from the inflorescence of female plants, from a selected clone of Cannabis for its specific cannabinoids profile.
Plants are cultivated in accordance to strict procedures that guarantee GAP application
and compliance to national regulation.
Cultivation are done in Switzerland in greenhouses or in the field. In order to assure the quality of Cannabis through the cultivation process, Linnea staff is present on site to monitor all procedures involved in planting, harvesting, cleaning, storing and transporting.
|Name of the plant
||Cannabis sativa L.
|Part of the plant used
||Solvent-oil extract of Cannabis rich in Cannabidiol (THC free)
||Cannabis extract, standardized in CBD (Cannabidiol)
||(-)-Cannabidiol (abbr. CBD)
Structural Formula of Cannabidiol